Longer lifetime oestrogen exposure tracked with slower ageing in a two-cohort study
In 112,381 postmenopausal women across UK Biobank and US NHANES, more lifetime oestrogen exposure was linked to a younger biological age and a modestly longer estimated lifespan — alongside higher cancer risk.
| Group | Value (years) |
|---|---|
| UK Biobank | 0.64 (0.3 to 0.97) |
| US NHANES | 1.35 (0.2 to 2.5) |
Women with more cumulative exposure to their own oestrogen over a lifetime showed signs of slower biological ageing and a modestly longer estimated lifespan, according to a prospective study of two large cohorts published on 8 November in BJOG [s1]. The associations were consistent across both cohorts for some measures — but the same exposure tracked with higher rates of breast and endometrial cancer, a trade-off the authors do not play down.
The hormone oestrogen falls sharply at menopause, and how much of it a woman is exposed to across her reproductive years varies with when she starts and stops menstruating, pregnancies and other factors. Whether that lifetime exposure relates to how the body ages, rather than to any single disease, is the question this study set out to probe [s1].
What the study did
Researchers drew on two population-based cohorts: the UK Biobank and the United States National Health and Nutrition Examination Survey, known as NHANES [s1]. The analysis covered 112,381 postmenopausal women in all — 107,218 from UK Biobank and 5,163 from US NHANES [s1].
Lifetime oestrogen exposure was captured with three indices built from reproductive history: reproductive lifespan, endogenous oestrogen exposure and total oestrogen exposure [s1]. Biological ageing — how old the body appears compared with calendar age — was measured using phenotypic age. The researchers then used linear regression to relate the exposure indices to accelerated phenotypic ageing, Cox models to assess mortality, and survival models to estimate life expectancy, adjusting for other factors [s1].
What it found
In the UK Biobank, higher scores on all three indices were inversely related to accelerated phenotypic ageing — that is, more lifetime oestrogen tracked with a biologically younger profile — with the associations generally strongest for reproductive lifespan and total oestrogen exposure [s1]. For the highest quartile of reproductive lifespan, the estimate was a reduction of 0.31 in phenotypic-age acceleration (95% confidence interval −0.40 to −0.22) [s1]. In US NHANES, the inverse association was clearest for total oestrogen exposure [s1].
Mortality moved in the same direction. Higher reproductive lifespan and total oestrogen exposure were generally associated with lower risks of all-cause, cardiovascular and respiratory death across both cohorts [s1]. Translated into years, the highest quartile of total oestrogen exposure was associated with an estimated 0.64 extra years of life expectancy at age 45 in the UK Biobank (95% CI 0.30 to 0.97) and 1.35 extra years in US NHANES (95% CI 0.20 to 2.50) [s1].
The counterweight is cancer. In the UK Biobank, reproductive lifespan and endogenous oestrogen exposure were associated with higher endometrial cancer incidence, and all three indices with higher breast cancer incidence [s1]. Oestrogen's relationship with the body is not uniformly protective.
How to read it
The strengths here are scale and replication: more than 112,000 women across two independent cohorts, with the headline associations appearing in both [s1]. That makes the direction of the finding — more lifetime oestrogen, slower measured ageing, slightly longer estimated life — hard to dismiss as a fluke of one dataset.
But this is observational, and the limits are important. The oestrogen indices are estimated from reproductive history, not measured hormone levels, so they are proxies. An association between a longer reproductive lifespan and longer life does not establish that oestrogen causes the longevity; the same reproductive history can mark underlying health, and the confidence intervals — especially the wide NHANES life-expectancy interval of 0.20 to 2.50 years — reflect real uncertainty [s1]. And the elevated cancer risk means these indices cannot be read as a simple "more is better" signal [s1]. The study describes a pattern in populations; it is not a reason for any individual to seek more oestrogen exposure.
What to watch
The open questions are mechanism and causation: whether measured hormone levels, rather than reproductive-history proxies, show the same link, and how the ageing benefit should be weighed against the cancer risk that travels with it [s1]. For context, see our coverage of menopause and of what the evidence shows on biological ageing.
This article describes a single observational study. It is not medical advice, and decisions about hormones and menopause belong with a woman's own clinicians.
Sources
- Lifetime Oestrogen Exposure Indices in Relation to Biological Aging and Future Life Expectancy: A Prospective Study of Two Cohorts — BJOG: An International Journal of Obstetrics & Gynaecology , November 8, 2026
More on
In a sham-controlled trial, vaginal laser added nothing for breast cancer survivors
Among 84 women on aromatase inhibitors, CO2 laser did no better than a fake laser for sexual function at 12 months. Both groups improved — on moisturisers and vibrators given to everyone.
A GBD study attributes 48,307 breast-cancer deaths in 2023 to high blood sugar
A Global Burden of Disease analysis finds the share of female breast-cancer deaths tied to high fasting plasma glucose rose from 1990 to 2023 and is projected to keep rising — but the design cannot prove causation.
Soy, isoflavones and the breast-cancer myth: what the evidence shows
The fear that soy fuels breast cancer is not supported by the human data; if anything, soy food intake tracks with lower recurrence and death after diagnosis. Its other health claims are weaker.
Your mammogram now reports breast density. Here is what that actually means.
Dense tissue raises breast-cancer risk and hides cancers on a mammogram. US facilities must now tell patients — but the evidence on what to do next is a real trade-off: more cancers found, more false alarms.